ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,842.91
0.11%
Dow Jones
42,518.28
0.52%
US Dollar vs MXN
20.502
-0.07%
Brent Oil
79.555
-0.18%
Bitcoin
96,580.65
0.08%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. ContraFect Corporation (CFRX)

  7. ContraFect Corporation (CFRX) Noticias

CFRX

ContraFect (CFRX)

ContraFect Corporation
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CFRX
FechaHoraFuenteTítuloSímboloCompañía
14/02/202413:24Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CFRXContraFect Corporation
15/11/202315:41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
03/11/202316:08Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CFRXContraFect Corporation
02/11/202323:16Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CFRXContraFect Corporation
30/10/202316:24Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CFRXContraFect Corporation
23/10/202315:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CFRXContraFect Corporation
16/10/202306:30GlobeNewswire Inc.ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical StudyNASDAQ:CFRXContraFect Corporation
25/09/202307:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CFRXContraFect Corporation
19/09/202307:30GlobeNewswire Inc.ContraFect to Present at the ASM/ESCMID Joint Conference on Drug DevelopmentNASDAQ:CFRXContraFect Corporation
18/09/202306:30GlobeNewswire Inc.ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370NASDAQ:CFRXContraFect Corporation
14/09/202315:05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:CFRXContraFect Corporation
28/08/202307:00GlobeNewswire Inc.ContraFect to Present at the World Anti-Microbial Resistance Congress 2023NASDAQ:CFRXContraFect Corporation
14/08/202315:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CFRXContraFect Corporation
14/08/202307:30GlobeNewswire Inc.ContraFect Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CFRXContraFect Corporation
27/06/202307:30GlobeNewswire Inc.ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 MillionNASDAQ:CFRXContraFect Corporation
27/06/202307:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CFRXContraFect Corporation
20/06/202307:59GlobeNewswire Inc.ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative PathogensNASDAQ:CFRXContraFect Corporation
08/06/202315:01GlobeNewswire Inc.ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023NASDAQ:CFRXContraFect Corporation
15/05/202315:28Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CFRXContraFect Corporation
15/05/202307:00GlobeNewswire Inc.ContraFect Reports First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CFRXContraFect Corporation
04/05/202305:05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:CFRXContraFect Corporation
28/04/202315:21Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:CFRXContraFect Corporation
26/04/202308:00GlobeNewswire Inc.ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the KneeNASDAQ:CFRXContraFect Corporation
20/04/202307:30GlobeNewswire Inc.ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative PathogensNASDAQ:CFRXContraFect Corporation
06/04/202307:30GlobeNewswire Inc.ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID MeetingNASDAQ:CFRXContraFect Corporation
03/04/202315:45Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:CFRXContraFect Corporation
03/04/202307:30GlobeNewswire Inc.ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the KneeNASDAQ:CFRXContraFect Corporation
31/03/202315:08Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CFRXContraFect Corporation
31/03/202307:30GlobeNewswire Inc.ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business UpdateNASDAQ:CFRXContraFect Corporation
02/03/202305:29Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:CFRXContraFect Corporation
 Showing the most relevant articles for your search:NASDAQ:CFRX

Su Consulta Reciente

BIT
UC78PZ
Unicredit Bank
BIT
UB486J
Unicredit Bank
BIT
F24513
Vontobel Financial Produ...
BIT
A33597
Aldburg Public
BIT
I08673
Intesa Sanpaolo
BIT
I09195
Intesa Sanpaolo
BIT
S28703
Societe Generale Effekten
BIT
JNKE
SSgA SPDR ETFs EUROPE I ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados